Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Marker TherapeuticsFRA:GX1 -2.65%34 EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus rates FRA:GX1 with a GF Score™ of 34/100. The stock has 1 warning sign investors should review. Among 939 Biotechnology companies, Marker Therapeutics ranks worse than 106496.17% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Marker Therapeutics EBITDA Margin % Related Terms
Marker Therapeutics EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Marker Therapeutics's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:GX1 vs PLUR, VYNE, LGVN: EBITDA Margin % Comparison
For the Biotechnology subindustry, Marker Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Marker Therapeutics EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Marker Therapeutics's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Marker Therapeutics's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Marker Therapeutics (FRA:GX1) has a EBITDA Margin % of 0.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Marker Therapeutics and its competitors. According to the industry distribution chart, Marker Therapeutics ranks #999999 out of 939 companies in the Biotechnology industry.
Is Marker Therapeutics' EBITDA Margin % too high?
Marker Therapeutics' current EBITDA Margin % is 0.00%. Based on the distribution chart, Marker Therapeutics ranks #999999 out of 939 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Marker Therapeutics has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Marker Therapeutics' EBITDA Margin % compare to PLUR and VYNE?
According to the Biotechnology industry distribution chart, Marker Therapeutics ranks #999999 out of 939 companies for EBITDA Margin %. This places Marker Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Marker Therapeutics and its competitors. Marker Therapeutics's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Marker Therapeutics stock overvalued right now?
Marker Therapeutics (FRA:GX1) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Marker Therapeutics' overall GF Score™ is 34/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Marker Therapeutics (FRA:GX1), the current EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from MAR-T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601), and Off-the-Shelf (OTS) products (MT-401-OTS).
34GF Score
Get the complete analysis for FRA:GX1
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:GX1 has been successfully added to your 
